Skip to main content

Advertisement

Log in

Opinion statement

Takayasu’s arteritis is a rare disease that causes arterial inflammation with resulting stenosis or aneurysm of affected vessels. It primarily affects young females and has a predilection for the aorta, its primary branches, and the pulmonary arteries. Patients may present with symptoms of organ ischemia, such as stroke or claudication, or with signs of arterial stenosis, such as absent pulses or asymmetric blood pressures. Most patients require chronic immunosuppressive therapy to control inflammation. The foundation of therapy is glucocorticoids, which are often used in combination with other immunosuppressive agents, such as methotrexate, azathioprine, or mycophenolate mofetil. The goal of systemic therapy is to induce and maintain disease remission, often defined as the absence of new arterial lesions, lack of systemic symptoms, and ability to taper prednisone to less than 10 mg/d. Promising results have been seen with the use of agents directed against tumor necrosis factor in patients who have failed to maintain remission with standard therapies. Revascularization procedures such as percutaneous transluminal angioplasty (PTA) or bypass grafting are reserved for patients who have critical organ ischemia or severe extremity claudication. Bypass grafting has a lower restenosis rate than PTA and is the preferred method of restoring blood flow to affected organs. Frequent laboratory testing is recommended to monitor for drug toxicity and signs of disease relapse. At each clinic visit, physicians should auscultate for bruits over primary arterial branches and evaluate for asymmetry between arm and leg blood pressures. Biannual radiographic imaging with magnetic resonance or CT angiography is helpful to examine for evidence of new aortic aneurysms or arterial stenoses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Weyand CM, Goronzy JJ: Medium-and large-vessel vasculitis. N Engl J Med 2003, 349:160–169.

    Article  PubMed  CAS  Google Scholar 

  2. Hall S, Barr W, Lie JT, et al.: Takayasu arteritis. A study of 32 North American patients. Medicine (Baltimore) 1985, 64:89–99.

    CAS  Google Scholar 

  3. Kerr GS, Hallahan CW, Giordano J, et al.: Takayasu arteritis. Ann Intern Med 1994, 120:919–929.

    PubMed  CAS  Google Scholar 

  4. Jain S, Kumari S, Ganguly NK, Sharma BK: Current status of Takayasu arteritis in India. Int J Cardiol 1996, 54(Suppl):S111–S116.

    PubMed  Google Scholar 

  5. Lupi-Herrera E, Sanchez-Torres G, Marcushamer J, et al.: Takayasu’s arteritis. Clinical study of 107 cases. Am Heart J 1977, 93:94–103.

    Article  PubMed  CAS  Google Scholar 

  6. Maksimowicz-McKinnon K, Clark TM, Hoffman GS: Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum 2007, 56:1000–1009.

    Article  PubMed  Google Scholar 

  7. Vanoli M, Daina E, Salvarani C, et al.: Takayasu’s arteritis: a study of 104 Italian patients. Arthritis Rheum 2005, 53:100–107.

    Article  PubMed  CAS  Google Scholar 

  8. Nakao K, Ikeda M, Kimata S, et al.: Takayasu’s arteritis. Clinical report of eighty-four cases and immunological studies of seven cases. Circulation 1967, 35:1141–1155.

    PubMed  CAS  Google Scholar 

  9. Ishikawa K, Maetani S: Long-term outcome for 120 Japanese patients with Takayasu’s disease. Clinical and statistical analyses of related prognostic factors. Circulation 1994, 90:1855–1860.

    PubMed  CAS  Google Scholar 

  10. Ueda H, Morooka S, Ito I, et al.: Clinical observation of 52 cases of aortitis syndrome. Jpn Heart J 1969, 10:277–288.

    PubMed  CAS  Google Scholar 

  11. Tso E, Flamm SD, White RD, et al.: Takayasu arteritis: utility and limitations of magnetic resonance imaging in diagnosis and treatment. Arthritis Rheum 2002, 46:1634–1642.

    Article  PubMed  Google Scholar 

  12. Hoffman GS, Ahmed AE: Surrogate markers of disease activity in patients with Takayasu arteritis. A preliminary report from The International Network for the Study of the Systemic Vasculitides (INSSYS). Int J Cardiol 1998, 66(Suppl 1):S191–S194; discussion S195.

    Article  PubMed  Google Scholar 

  13. Murray L, Philippi E: 2007 Red Book. Montvale, NJ: Thomson Healthcare Inc.; 2007.

    Google Scholar 

  14. Hoffman GS, Leavitt RY, Kerr GS, et al.: Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 1994, 37:578–582.

    Article  PubMed  CAS  Google Scholar 

  15. Valsakumar AK, Valappil UC, Jorapur V, et al.: Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu’s arteritis. J Rheumatol 2003, 30:1793–1798.

    PubMed  CAS  Google Scholar 

  16. Daina E, Schieppati A, Remuzzi G: Mycophenolate mofetil for the treatment of Takayasu arteritis: report of three cases. Ann Intern Med 1999, 130:422–426.

    PubMed  CAS  Google Scholar 

  17. Shelhamer JH, Volkman DJ, Parrillo JE, et al.: Takayasu’s arteritis and its therapy. Ann Intern Med 1985, 103:121–126.

    PubMed  CAS  Google Scholar 

  18. Ozen S, Duzova A, Bakkaloglu A, et al.: Takayasu arteritis in children: preliminary experience with cyclophosphamide induction and corticosteroids followed by methotrexate. J Pediatr 2007, 150:72–76.

    Article  PubMed  CAS  Google Scholar 

  19. Hoffman GS, Merkel PA, Brasington RD, et al.: Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004, 50:2296–2304.

    Article  PubMed  CAS  Google Scholar 

  20. Tato F, Rieger J, Hoffmann U: Refractory Takayasu’s arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab. Int Angiol 2005, 24:304–307.

    PubMed  CAS  Google Scholar 

  21. Hoffman GS: Takayasu arteritis: lessons from the American National Institutes of Health experience. Int J Cardiol 1996, 54(Suppl):S99–S102.

    Article  PubMed  Google Scholar 

  22. Weaver FA, Yellin AE, Campen DH, et al.: Surgical procedures in the management of Takayasu’s arteritis. J Vasc Surg 1990, 12:429–437; discussion 438–439.

    Article  PubMed  CAS  Google Scholar 

  23. Sharma S, Gupta H, Saxena A, et al.: Results of renal angioplasty in nonspecific aortoarteritis (Takayasu disease). J Vasc Interv Radiol 1998, 9:429–435.

    Article  PubMed  CAS  Google Scholar 

  24. Sharma BK, Jain S, Bali HK, et al.: A follow-up study of balloon angioplasty and de-novo stenting in Takayasu arteritis. Int J Cardiol 2000, 75(Suppl 1):S147–S152.

    Article  PubMed  Google Scholar 

  25. Liang P, Hoffman GS: Advances in the medical and surgical treatment of Takayasu arteritis. Curr Opin Rheumatol 2005, 17:16–24.

    Article  PubMed  CAS  Google Scholar 

  26. Yao JS, Shen F, Young WL, Yang GY: Comparison of doxycycline and minocycline in the inhibition of VEGF-induced smooth muscle cell migration. Neurochem Int 2007, 50:524–530.

    Article  PubMed  CAS  Google Scholar 

  27. Yao JS, Chen Y, Zhai W, et al.: Minocycline exerts multiple inhibitory effects on vascular endothelial growth factor-induced smooth muscle cell migration: the role of ERK1/2, PI3K, and matrix metalloproteinases. Circ Res 2004, 95:364–371.

    Article  PubMed  CAS  Google Scholar 

  28. Lee CZ, Yao JS, Huang Y, et al.: Dose-response effect of tetracyclines on cerebral matrix metalloproteinase-9 after vascular endothelial growth factor hyperstimulation. J Cereb Blood Flow Metab 2006, 26:1157–1164.

    PubMed  CAS  Google Scholar 

  29. Matsuyama A, Sakai N, Ishigami M, et al.: Minocycline for the treatment of Takayasu arteritis. Ann Intern Med 2005, 143:394–395.

    PubMed  Google Scholar 

  30. Rodriguez-Pla A, Bosch-Gil JA, Rossello-Urgell J, et al.: Metalloproteinase-2 and-9 in giant cell arteritis: involvement in vascular remodeling. Circulation 2005, 112:264–269.

    Article  PubMed  CAS  Google Scholar 

  31. Rittner HL, Kaiser M, Brack A, et al.: Tissue-destructive macrophages in giant cell arteritis. Circ Res 1999, 84:1050–1058.

    PubMed  CAS  Google Scholar 

  32. Matsuyama A, Sakai N, Ishigami M, et al.: Matrix metal-loproteinases as novel disease markers in Takayasu arteritis. Circulation 2003, 108:1469–1473.

    Article  PubMed  CAS  Google Scholar 

  33. Weinblatt M, Combe B, Covucci A, et al.: Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and non-biologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 2006, 54:2807–2816.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Curry L. Koening.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koening, C.L., Langford, C.A. Takayasu’s arteritis. Curr Treat Options Cardio Med 10, 164–172 (2008). https://doi.org/10.1007/s11936-008-0018-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-008-0018-9

Keywords

Navigation